

January 12, 2026

To,
BSE Ltd
PJ Towers,
Dalal Street,
Mumbai – 400001.
BSE Scrip Code: 532372

To,
National Stock Exchange of India Ltd.
Exchange Plaza, Bandra Kurla
Complex, Bandra, East, Mumbai –
400051
NSE Symbol: VIRINCHI

To,
Virinchi Limited
8-2-672 / 5 & 6, 4th Floor,
Ilyas Mohammed Khan
Estate, Road No.1, Banjara
Hills, Hyderabad,
Telangana – 500034.

Dear Sir/Madam,

Sub: - Reporting under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

With reference to the above, please find enclosed reporting under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011 pursuant to the allotment of 86,00,000 Convertible Equity Warrants on January 08, 2026 & 74,00,000 Convertible Equity Warrants on January 09, 2026 on preferential basis in Virinchi Limited.

This is for your information and records.


Thanking you

Yours Truly

For Vivo Bio Tech Limited



Kalyan Ram Mangipudi
Whole-time Director
02012580



Disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011


Name of the Target Company (TC)	Virinchi Limited		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Vivo Bio tech Limited		
Whether the acquirer belongs to Promoter/Promoter group	Yes, Promoter Group		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	BSE Limited NSE Limited		
Details of the acquisition as follows	Number	% w.r.t. total share/voting capital wherever applicable(*)	% w.r.t. total diluted share/voting capital of the TC (**)
Before the acquisition under consideration, holding of acquirer along with PACs of:			
a) Shares carrying voting rights	-	-	-
b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	-	-	-
c) Voting rights (VR) otherwise than by equity shares	-	-	-
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	-	-	-
e) Total (a+b+c+d)	-	-	-
Details of acquisition:			
a) Shares carrying voting rights acquired	-	-	-
b) VRs acquired otherwise than by shares	-	-	-
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired	1,60,00,000	15.59	12.69
d) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	-	-	-
e) Total (a+b+c+/-d)	1,60,00,000	15.59	12.69

After the acquisition, holding of acquirer along with PACs of:			
a) Shares carrying voting rights	-	-	-
b) VRs otherwise than by shares	-	-	-
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition	1,60,00,000	15.59	12.69
d) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	-	-	-
e) Total (a+b+c+d)	1,60,00,000	15.59	12.69
Mode of acquisition (e.g. open market / off market / public issue / rights issue / preferential allotment / inter-se transfer/encumbrance, etc).	Preferential Allotment of Convertible Equity Warrants		
Salient features of the securities acquired including time till redemption, ratio at which it can be converted into equity shares, etc.	Convertible Equity Warrants issued and allotted on Preferential Basis with a right to Warrant Holder to apply for and get allotted one equity share of face value of Rs. 10/- ranking in all respects pari-passu with the existing equity shares of the Company, to be converted, within a period of 18 months from the date of allotment of Warrants, at an issue price of Rs. 28/-.		
Date of acquisition of/ date of receipt of intimation of allotment of shares / VR/ warrants/convertible securities/any other instrument that entitles the acquirer to receive shares in the TC.	January 08, 2026 & January 09, 2026 (Date of allotment of Convertible Equity Warrants)		
Equity share capital / total voting capital of the TC before the said acquisition	10,26,46,896 Equity shares of Rs. 10 each aggregating Rs. 102,64,68,960/-		
Equity share capital/ total voting capital of the TC after the said acquisition	10,26,46,896 Equity shares of Rs. 10 each aggregating Rs. 102,64,68,960/-		
Total diluted share/voting capital of the TC after the said acquisition	12,60,46,896 Equity shares of Rs. 10 each aggregating Rs. 126,04,68,960**		


Diluted Share Capital:

**The above Equity share capital is based on the assumption of the 2,34,00,000 outstanding Warrants shall be converted into equity shares, in one or more tranches.

For Vivo Bio Tech Limited



Kalyan Ram Mangipudi
Whole-time Director
02012580



Place: Hyderabad

Date: January 12, 2026